Jane Street Group LLC Decreases Position in BioAtla, Inc. (NASDAQ:BCAB)

Jane Street Group LLC reduced its stake in BioAtla, Inc. (NASDAQ:BCAB) by 64.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,087 shares of the company’s stock after selling 87,614 shares during the period. Jane Street Group LLC owned 0.10% of BioAtla worth $86,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BCAB. AQR Capital Management LLC acquired a new stake in BioAtla during the 2nd quarter worth $872,000. Scion Asset Management LLC purchased a new stake in shares of BioAtla in the second quarter valued at about $869,000. GSA Capital Partners LLP purchased a new stake in shares of BioAtla in the third quarter valued at about $623,000. Bank of Montreal Can boosted its stake in shares of BioAtla by 55.1% during the second quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock worth $554,000 after buying an additional 143,521 shares during the period. Finally, American Century Companies Inc. increased its position in BioAtla by 36.1% in the 2nd quarter. American Century Companies Inc. now owns 43,391 shares of the company’s stock valued at $59,000 after acquiring an additional 11,503 shares during the period. Institutional investors and hedge funds own 77.23% of the company’s stock.

BioAtla Stock Performance

BioAtla stock opened at $0.50 on Wednesday. The firm has a market capitalization of $24.17 million, a price-to-earnings ratio of -0.29 and a beta of 1.17. BioAtla, Inc. has a fifty-two week low of $0.45 and a fifty-two week high of $4.02. The stock’s fifty day moving average is $1.27 and its two-hundred day moving average is $1.59.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12. The company had revenue of $11.00 million during the quarter. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. As a group, sell-side analysts forecast that BioAtla, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

BioAtla Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.